Total Utang marang Modal Syndax (SNDX)

Syndax Pharmaceuticals, Inc. - logo grafis emiten SNDX

Syndax Pharmaceuticals (SNDX) aims for dominance in the leukemia treatment niche through the introduction of revumenib. The balance of debt and equity clearly demonstrates the financial leverage dynamics, where the value 40.59 represents the current metric. The absence of stable cash flows makes the company dependent on external financing, yet positive Phase 3 trial results create strong momentum for asset value growth.

syndax.com (SNDX): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 31.10.2026

Rincian metrik lan analitis perusahaan Syndax Corp (SNDX)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Syndax Pharmaceuticals, Inc.|SNDX - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Syndax Pharmaceuticals|SNDX - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Syndax Pharmaceuticals|SNDX - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku syndax.com|SNDX - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Syndax Pharmaceuticals|SNDX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Syndax Pharmaceuticals|SNDX - Kewajiban utang agregat|Utang marang nilai buku Syndax Pharmaceuticals|SNDX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Syndax Pharmaceuticals|Likuiditas cepet syndax.com
- data bathi resik lan rasio valuasi:
SNDX - Bathi resik perusahaan
Pambiji fundamental perusahaan:Syndax Pharmaceuticals, Inc.
Produk dadi Syndax Pharmaceuticals

Assessing the financial stability of Syndax Pharmaceuticals (SNDX) requires an analysis of its liability structure. This ratio compares total borrowed funds to equity, determining the proportion of assets controlled by creditors. By monitoring changes in the debt-to-equity ratio, an investor can track the dynamics of the debt load. For an oncology drug developer, moderate leverage is critical when capitalizing patents. An optimal debt balance ensures the development of high-margin products without the risk of bankruptcy.

Analisis pesaing Syndax Pharmaceuticals

TGTX (TG Therapeutics) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Arcellx Inc (ACLX)|Total Utang marang Modal IRON|Total Utang marang Modal Kura (KURA)|Utang marang Ekuitas ADC Therapeutics ADCT|FHTX: Rasio Utang marang Ekuitas|Vor Biopharma - Total Utang marang Modal|Nkarta, Inc. (NKTX) - Rasio Total Utang marang Ekuitas|COEP: Total Utang marang Modal|Utang marang Modal Actinium Corp (ATNM)|Utang marang Ekuitas Estrella Immunopharma|CASI: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Utang marang Ekuitas|APTO - Utang marang Ekuitas|BPTH: Utang marang Ekuitas|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)